文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Luxton T, Parker L A, Siegel S

Department of Psychology, Wilfrid Laurier University, Waterloo, Ontario, Canada.

Prog Neuropsychopharmacol Biol Psychiatry. 1996 Jul;20(5):857-72. doi: 10.1016/0278-5846(96)00064-4.

Ibogaine, a proposed anti-addictive agent, has been found to interfere with the acquisition of a weak morphine-induced place preference. The present series of experiments determined if ibogaine would interfere with the expression of a previously established morphine (5 mg/kg) place preference. 2. A single injection of 40 mg/kg of ibogaine 24 h, 12 h or 4 h prior to the preference test (Experiment 1) or 80 mg/kg of ibogaine 24 hr prior to the preference test (Experiment 3) did not interfere with the expression of a morphine conditioned place preference. 3. Furthermore, two injections of 40 mg/kg of ibogaine 48 h and 24 h or 24 h and 4 h prior to testing (Experiment 2) did not interfere with the expression of a morphine place preference. 4. Ibogaine appears to be incapable of attenuating the expression of a previously established one-trial morphine place preference.

伊波加因是一种被提议的抗成瘾药物，已发现它会干扰弱吗啡诱导的位置偏爱形成。本系列实验确定伊波加因是否会干扰先前建立的吗啡（5毫克/千克）位置偏爱表达。2. 在偏爱测试前24小时、12小时或4小时单次注射40毫克/千克伊波加因（实验1）或在偏爱测试前24小时单次注射80毫克/千克伊波加因（实验3），均未干扰吗啡条件性位置偏爱表达。3. 此外，在测试前48小时和24小时或24小时和4小时两次注射40毫克/千克伊波加因（实验2），也未干扰吗啡位置偏爱表达。4. 伊波加因似乎无法减弱先前建立的单次试验吗啡位置偏爱表达。

Luxton T, Parker L A, Siegel S

Department of Psychology, Wilfrid Laurier University, Waterloo, Ontario, Canada.

Prog Neuropsychopharmacol Biol Psychiatry. 1996 Jul;20(5):857-72. doi: 10.1016/0278-5846(96)00064-4.

Ibogaine, a proposed anti-addictive agent, has been found to interfere with the acquisition of a weak morphine-induced place preference. The present series of experiments determined if ibogaine would interfere with the expression of a previously established morphine (5 mg/kg) place preference. 2. A single injection of 40 mg/kg of ibogaine 24 h, 12 h or 4 h prior to the preference test (Experiment 1) or 80 mg/kg of ibogaine 24 hr prior to the preference test (Experiment 3) did not interfere with the expression of a morphine conditioned place preference. 3. Furthermore, two injections of 40 mg/kg of ibogaine 48 h and 24 h or 24 h and 4 h prior to testing (Experiment 2) did not interfere with the expression of a morphine place preference. 4. Ibogaine appears to be incapable of attenuating the expression of a previously established one-trial morphine place preference.

伊波加因是一种被提议的抗成瘾药物，已发现它会干扰弱吗啡诱导的位置偏爱形成。本系列实验确定伊波加因是否会干扰先前建立的吗啡（5毫克/千克）位置偏爱表达。2. 在偏爱测试前24小时、12小时或4小时单次注射40毫克/千克伊波加因（实验1）或在偏爱测试前24小时单次注射80毫克/千克伊波加因（实验3），均未干扰吗啡条件性位置偏爱表达。3. 此外，在测试前48小时和24小时或24小时和4小时两次注射40毫克/千克伊波加因（实验2），也未干扰吗啡位置偏爱表达。4. 伊波加因似乎无法减弱先前建立的单次试验吗啡位置偏爱表达。